Supriya Lifescience IPO details (16 – 20 Dec), (Price ₹ 265 to 274)
Listing date and Listing Price of Supriya Lifescience IPO:
- Supriya Lifescience IPO listed on BSE and NSE exchanges on – Click Here
- Listing Price of Supriya Lifescience IPO on NSE – Click Here
- Listing Price of Supriya Lifescience IPO on BSE – Click Here
Grey Market premium (GMP) price of Supriya Lifescience IPO :
Grey Market premium (GMP) price of Supriya Lifescience IPO is ₹__. Grey Market premium (GMP) of Supriya Lifescience IPO means, unofficially if someone buys or sells his application at a fixed rate irrespective of listing price. Check latest GMP of all IPOs.
Supriya Lifescience IPO Allotment link status on Link Intime:
- Check the allotment status of Supriya Lifescience IPO on the below link given by Link Intime.
- Supriya Lifescience IPO Allotment Link – https://linkintime.co.in/MIPO/Ipoallotment.html
Supriya Lifescience IPO Allotment link status on Link Intime can be checked by Application No or DP Client ID or PAN.
Supriya Lifescience IPO subscription status details:
|QIB (Qualified Institl. Bidders)||NIB (Non-institutional Investor)||RII (Retail Individual Investor)||Total No. of times applied|
|No. of shares offered||79,24,527||39,62,263||26,41,509||1,45,28,299|
Supriya Lifescience IPO highlights:
|Supriya Lifescience IPO bid Opens on||16 Dec 2021|
|Supriya Lifescience IPO bid Closes on||20 Dec 2021|
|Post issue Modification Period||21 Dec -2021 (10.00 A.M. to 11.00 A.M.)|
|Cut-off time for UPI Mandate Confirmation||21 Dec -2021 (upto 12:00 PM)|
|Issue type||100% Book Building|
|Supriya Lifescience IPO issue size||₹ 700 Cr|
|Face value of each equity share||Rs. 2|
|Supriya Lifescience IPO Price band||Rs 265 to Rs 274 per share|
|Supriya Lifescience IPO market lot||54 equity shares and multiples of 54|
|Supriya Lifescience IPO minimum order quantity||54 equity shares|
|Pre IPO equity share of promoters of Supriya Lifescience||99.98 %|
|Post IPO paid-up equity share of promoters of Supriya Lifescience||68.24 %|
|QIB portion reservation in Supriya Lifescience IPO||75 %|
|NIB portion reservation in Supriya Lifescience IPO||15 %|
|Retail portion reservation in Supriya Lifescience IPO||10 %|
|Retail individual bidder can apply in Supriya Lifescience IPO||up to 2 lakh (200,000) – Maximum 13 Lot|
|Retail individual discount in Supriya Lifescience IPO||NA|
|Employees can apply in Supriya Lifescience IPO||up to 5 lakh (500,000)|
|Employees Reservation in Supriya Lifescience IPO||NA|
|Employees Discount in Supriya Lifescience IPO||NA|
|Listing of Supriya Lifescience at Exchanges||NSE, BSE|
|Fund raised from Anchor Investors in Pre-IPO of Supriya Lifescience||NA|
|Registrar of Supriya Lifescience IPO issue||Link Intime India Private Limited|
Supriya Lifescience IPO important dates regarding bidding, allotment, listing, refund etc. :
The probable dates regarding bidding, allotment, listing, refund of Supriya Lifescience IPO are mentioned below.
|Supriya Lifescience IPO opens on||16.12.2021|
|Supriya Lifescience IPO Closes on||20.12.2021|
|Allotment basis date of Supriya Lifescience IPO||23.12.2021|
|Money refund date of Supriya Lifescience IPO||24.12.2021|
|Shares of Supriya Lifescience in Demat Account||27.12.2021|
|Supriya Lifescience IPO listing date on NSE, BSE||28.12.2021|
How much shares of Supriya Lifescience IPO are being offered?
|Type of Issue (Fresh / OFS)||No. of Equity shares offered||Amount of Equity shares|
|Total Issue size||₹ 700 Crore|
|Fresh Issue size||–||₹ 200 Crore|
|Offer for Sale (OFS)||–||₹ 500 Crore|
Supriya Lifescience financial statements details:
|(₹ million)||(₹ million)||(₹ million)|
|Profit After Tax||1,238.28||733.74||394.24|
IPO Red Herring Prospectus (RHP) of Supriya Lifescience:
Objectives of the Supriya Lifescience IPO Issue: (Source – RHP)
The Fresh Issue
Our Company proposes to utilise the Net Proceeds towards funding of the following objects: 1. Funding capital expenditure requirements of our Company; 2. Repayment and/ or pre-payment, in full or part, of certain borrowings availed by our Company and 3. General corporate purposes.
Business of Supriya Lifescience: (Source – RHP)
We are one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients (“APIs”), with a focus on research and development. As of October 31, 2021, we have niche product offerings of 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and antiallergic. We have consistently been the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India, contributing to 45-50% and 60-65%, respectively, of the API exports from India, between Fiscal 2017 and 2021.
We were among the largest exporters of Salbutamol Sulphate in India contributing to 31% of the API exports from India in FY 2021 in volume terms (Source: CRISIL Report). Our pharmaceutical business is organized into domestic and export sales, according to the geographies in which we operate. From April 1, 2020 until October 31 2021, our products were exported to 86 countries to 1,296 customers including 346 distributors. We have grown our API business in several countries across :
(i) Europe, which contributed to 17.40 % and 18.53 % of revenue from operation for the year ended March 31, 2021 and for the six month period ended September 30, 2021, respectively; (ii) Latin America, which contributed to 19.15 % and 12.01 % of revenue from operation for the year ended March 31, 2021 and for the six month period ended September 30, 2021, respectively; (iii) Asia (excluding India), which contributed to 29.27 % and 36.76 % of revenue from operation for the year ended March 31, 2021 and for the six month period ended September 30, 2021, respectively; (iv) North America), which contributed to 4.76 % and 2.36 % of revenue from operation for the year ended March 31, 2021 and for the six month period ended September 30, 2021, respectively; and (vi) India, which contributed to 22.53% and 26.43% of revenue from operation for the year ended March 31, 2021 and for the six month period ended September 30, 2021, respectively.
Go Back to – IPO Dashboard for other IPOs:
Disclaimer: Kindly verify from RHP and concerned company for any clarification.
If you liked this article, kindly share it on any platform, whatsapp, facebook, twitter, Linkedin etc. below to keep us motivated.